The Retaplase,recombinant for Inject, cataloged under National Stock Number 6505-01-477-6768, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Ekr Therapeutics Incorporated. The record lists 3 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 3 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: EA.
| Parameter | Value |
|---|---|
| NSN | 6505-01-477-6768 |
| Primary Part Number | NDC10122-0141-02 |
| Item Name | Retaplase,recombinant for Inject |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Ekr Therapeutics Incorporated |
| Status | ACTIVE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | EA |
| Part Number | Manufacturer |
|---|---|
| 817783 | Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office (USA) |
| NDC10122-0141-02 PRIMARY | Ekr Therapeutics Incorporated (USA) |
| NDC10122-0141-02 | Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office (USA) |
| Reference | Meaning |
|---|---|
| RETAVASE KIT | 5/1 Secondary reference Ekr Therapeutics Incorporated |
| 1578957 | 5/1 Secondary reference U.S. Government activity |
| 6505NCM206364 | 5/1 Secondary reference Defense Medical Standardization Board |
NSN 6505-01-477-6768 is a Retaplase,recombinant for Inject, manufactured by Ekr Therapeutics Incorporated, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-477-6768 has 3 manufacturer part numbers on file: 817783 (Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office), NDC10122-0141-02 (Ekr Therapeutics Incorporated), NDC10122-0141-02 (Amerisourcebergen Drug Corp Dba Amerisourcebergen Drug Corp Div Corporate Office).
Key specifications for NDC10122-0141-02: Special Features: RETAVASE IS A TISSUE PLASMINOGEN ACTIVATOR (TPA) INDICATED FOR TREATMENT OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) TO REDUCE THE RISK OF DEATH AND HEART FAILURE; LYOPHILIZED POWDER KIT FOR IV INJECTION; CONTAINS: 2 SINGLE-USE RETAVASE 10-UNIT VIALS; 2-SINGLE-USE PREFILLED STERILE WATER FOR INJECTION; 2 SYRINGE PLUNGERS; 2 STERILE 10ML GRADUATED SYRINGES; 2 STERILE RECONSTITUTION SPIKES; 1 QUICK REFERENCE GUIDE AND 1 PACKAGE INSERT; BOX SHOULD REMAIN SEALED TO PROTECT THE LYOPHILISATE FROM EXPOSURE TO LIGHT. STORE KIT AT 2 TO 25 DEGREES CELSIUS.; Part Name Assigned by Controlling Agency: RETEPLASE, INTRAVENOUS SOLUTION KIT, 2 VIALS(10 UNITS PER VIAL). 0 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.